Search results for "decompensation"

showing 10 items of 74 documents

Comparison of DMEK and DSAEK in Eyes With Endothelial Decompensation After Previous Penetrating Keratoplasty.

2021

PURPOSE Posterior lamellar keratoplasty is increasingly applied in patients with endothelial decompensation after penetrating keratoplasty (PK). The aim of this study was to compare the results of Descemet membrane endothelial keratoplasty (DMEK) and Descemet stripping automated endothelial keratoplasty (DSAEK) after PK. METHODS In this retrospective study, clinical data of 30 patients who received DMEK (n = 19) or DSAEK (n = 11) for endothelial decompensation after PK were evaluated. All lamellar keratoplasties were performed at the Department of Ophthalmology at University Hospital Mainz, Germany. Primary end point included best-corrected visual acuity, and secondary end points included e…

AdultMalemedicine.medical_specialtyVisual acuityDescemet membraneVisual AcuityCell CountCorneal DiseasesYoung AdultOphthalmologymedicineHumansDecompensationIn patientPostoperative PeriodAgedRetrospective StudiesAged 80 and overGraft rejectionbusiness.industryGraft SurvivalEndothelial CellsCorneal Endothelial Cell LossMiddle AgedUniversity hospitalDescemet stripping automated endothelial keratoplastyEndothelial cell densityOphthalmologyFemalemedicine.symptombusinessDescemet Stripping Endothelial KeratoplastyKeratoplasty PenetratingCornea
researchProduct

A bi-allelic loss-of-function SARS1 variant in children with neurodevelopmental delay, deafness, cardiomyopathy, and decompensation during fever

2021

Aminoacyl-tRNA synthetases (aaRS) are ubiquitously expressed enzymes responsible for ligating amino acids to their cognate tRNA molecules through an aminoacylation reaction. The resulting aminoacyl-tRNA is delivered to ribosome elongation factors to participate in protein synthesis. Seryl-tRNA synthetase (SARS1) is one of the cytosolic aaRSs and catalyzes serine attachment to tRNASer . SARS1 deficiency has already been associated with moderate intellectual disability, ataxia, muscle weakness, and seizure in one family. We describe here a new clinical presentation including developmental delay, central deafness, cardiomyopathy, and metabolic decompensation during fever leading to death, in a…

AtaxiabrainCardiomyopathySARS1Loss of HeterozygosityBiologyAmino Acyl-tRNA Synthetaseschemistry.chemical_compounddeafnessdeathGeneticsmedicineProtein biosynthesisMissense mutationHumansDecompensationaminoacyl-tRNA synthetaseChildtRNAGenetics (clinical)GeneticsaminoacylationAminoacyl tRNA synthetasemedicine.diseaseElongation factorchemistryintellectual disabilityTransfer RNAmedicine.symptomCardiomyopathiesHuman mutation
researchProduct

Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with…

2017

Summary Background We ran a compassionate use nationwide programme (ABACUS) to provide access to ombitasvir, paritaprevir, and ritonavir, with dasabuvir, plus ribavirin for hepatitis C virus (HCV) genotype 1 infection and ombitasvir, paritaprevir, and ritonavir, plus ribavirin for HCV genotype 4 infection in patients with cirrhosis at high risk of decompensation while approval of these regimens was pending in Italy. Methods In this prospective observational study, we collected data from a compassionate use nationwide programme from March 17, 2014, to May 28, 2015. Patients with HCV genotype 1 infection and cirrhosis at high risk of decompensation were given coformulated ombitasvir (25 mg), …

CyclopropanesCompassionate Use TrialsLiver CirrhosisMalechemistry.chemical_compound0302 clinical medicine2-NaphthylamineHCV direct-acting antiviral mixed cryoglobulinemia RBVAnilides030212 general & internal medicineLongitudinal StudiesProspective StudiesChronicAdult; Aged; Anilides; Antiviral Agents; Carbamates; Compassionate Use Trials; Drug Therapy Combination; Female; Genotype; Hepatitis C Chronic; Humans; Liver Cirrhosis; Longitudinal Studies; Macrocyclic Compounds; Male; Middle Aged; Prospective Studies; Ribavirin; Ritonavir; Sulfonamides; Treatment Outcome; UracilSettore MED/12 - GastroenterologiaSulfonamidesDasabuvirHCV DAAGastroenterologyvirus diseasesValineMiddle AgedSettore MED/07 - Microbiologia e Microbiologia ClinicaHepatitis CTreatment OutcomeGastroenterology; HepatologyCombinationDrug Therapy Combination030211 gastroenterology & hepatologyFemalemedicine.drugAdultmedicine.medical_specialtyMacrocyclic CompoundsProlineGenotypeLactams MacrocyclicAdult; Aged; Anilides; Antiviral Agents; Carbamates; Compassionate Use Trials; Drug Therapy Combination; Female; Genotype; Hepatitis C Chronic; Humans; Liver Cirrhosis; Longitudinal Studies; Macrocyclic Compounds; Male; Middle Aged; Prospective Studies; Ribavirin; Ritonavir; Sulfonamides; Treatment Outcome; Uracil; Hepatology; GastroenterologyHepatitis C virus genotype 1 Hepatitis C virus genotype 4 decompensated liver cirrhosis antiviral therapy dasabuvir ombitasvir paritaprevirHepatology; GastroenterologyAntiviral Agents03 medical and health sciencesDrug TherapyInternal medicineRibavirinmedicineHumansDecompensationAdverse effectUracilAgedRitonavirHepatologybusiness.industryRibavirinHepatitis C ChronicVirologyOmbitasvirClinical trialchemistryParitaprevirRitonavirCarbamatesbusiness
researchProduct

Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis

2018

Purpose: To analyse safety and efficacy of treatment based on ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in the sub-group of GT1 patients older than 65 years. Methods: We collected data extracted from the ABACUS compassionate-use nationwide Italian programme, in patients with cirrhosis due to hepatitis C virus (HCV) Genotype-1 (GT1) or 4 and at high risk of decompensation. GT1-HCV-infected patients received once-daily ombitasvir/paritaprevir, with the pharmacokinetic enhancer ritonavir (25/150/100 mg) and twice-daily dasabuvir (250 mg) plus Ribavirin (RBV) (OBV/PTV/r + DSV + RBV) for 12 (GT1b) or 24 (GT1a) weeks. Endpoints were to evaluate safety and efficacy, the latter def…

CyclopropanesLiver CirrhosisMaleCirrhosis;Dasabuvir;Elderly;Ombitasvir;ParitaprevirCirrhosis; Dasabuvir; Elderly; Ombitasvir; Paritaprevir; Aged; Aged; 80 and over; Anilides; Antiviral Agents; Biomarkers; Carbamates; Female; Hepacivirus; Hepatitis C; Chronic; Humans; Liver Cirrhosis; Macrocyclic Compounds; Male; Ribavirin; Ritonavir; Sulfonamides; Treatment Outcome; Uracil; Drug Therapy; Combination; GenotypeParitaprevirCirrhosis Dasabuvir Elderly Ombitasvir Paritaprevir Microbiology (medical) Infectious DiseasesCirrhosis; Dasabuvir; Elderly; Ombitasvir; Paritaprevir; Aged; Aged 80 and over; Anilides; Antiviral Agents; Biomarkers; Carbamates; Female; Hepacivirus; Hepatitis C Chronic; Humans; Liver Cirrhosis; Macrocyclic Compounds; Male; Ribavirin; Ritonavir; Sulfonamides; Treatment Outcome; Uracil; Drug Therapy Combination; Genotype; Microbiology (medical); Infectious DiseasesHepacivirusGastroenterologychemistry.chemical_compound0302 clinical medicineElderly2-Naphthylamine80 and overMedicineAnilides030212 general & internal medicineChronicAged 80 and overSulfonamidesDasabuvirValineGeneral MedicineHepatitis CHepatitis CTreatment OutcomeInfectious DiseasesCirrhosisCombination030211 gastroenterology & hepatologyDrug Therapy CombinationFemaleDasabuvirMacrocyclic CompoundCirrhosis; Dasabuvir; Elderly; Ombitasvir; Paritaprevir; Microbiology (medical); Infectious Diseasesmedicine.drugHumanMicrobiology (medical)medicine.medical_specialtyMacrocyclic CompoundsProlineGenotypeLactams MacrocyclicSettore MED/12 - GASTROENTEROLOGIALiver CirrhosiSulfonamideAntiviral Agents03 medical and health sciencesDrug TherapyInternal medicineRibavirinHumansDecompensationUracilAgedHepatitisAntiviral AgentCirrhosiHepaciviruRitonavirbusiness.industryRibavirinSettore MED/09 - MEDICINA INTERNAAnilideBiomarkerHepatitis C Chronicmedicine.diseaseCirrhosis; Dasabuvir; Elderly; Ombitasvir; Paritaprevir; Aged; Aged 80 and over; Anilides; Antiviral Agents; Biomarkers; Carbamates; Female; Hepacivirus; Hepatitis C Chronic; Humans; Liver Cirrhosis; Macrocyclic Compounds; Male; Ribavirin; Ritonavir; Sulfonamides; Treatment Outcome; Uracil; Drug Therapy Combination; GenotypeOmbitasvirOmbitasvirchemistryParitaprevirCarbamateRitonavirCarbamatesbusinessBiomarkers
researchProduct

Morphometric Examination of the Dilated Rat Ureter

1987

Dilatations of the ureter are known in rats with diabetes insipidus as well as after the administration of diuretics (Wladimiroff 1975). Nevertheless, similarities to congenital deformities, such as the primary megaureter, have not been established to date. It has not yet been determined whether in the fetus increased diuresis can lead to a functional overstrain of the transport capacity of the ureter and thus to mutations in the sense of a congenital megaurter. In addition to the direct influence of increased diuresis, teratogenic effects of the administered diuretics during pregnancy are possible. Furthermore, it should be determined whether the dilatation can be classified as an adaptive…

FetusPregnancymedicine.medical_specialtyMegaureterbusiness.industryUrologymedicine.diseaseTeratologyUretermedicine.anatomical_structureDiabetes insipidusmedicineDecompensationbusinessPathological
researchProduct

Occurrence of hepatocellular carcinoma and decompensation in western european patients with cirrhosis type B

1995

To examine the morbidity of compensated cirrhosis type B, a cohort of 349 Western European, white patients (86% men; mean age, 44 years) with biopsy-proven cirrhosis was followed up for a mean period of 73 months and was studied for occurrence of hepatocellular carcinoma (HCC) and decompensation. At entry into the study all patients were tested for hepatitis B e antigen (HBeAg; 34% of patients were HBeAg-positive) and antibody to hepatitis delta virus (anti-HDV; 20% of patients were anti-HDV-positive); 48% of 252 patients tested were hepatitis B virus (HBV)-DNA-positive. During follow-up HCC developed in 32 (9%) of the 349 patients and decompensation was observed in 88 (28%) of 317 tumor-fr…

First episodeHepatitis B virusmedicine.medical_specialtyPathologyCirrhosisHepatologybusiness.industryIncidence (epidemiology)virus diseasesHepatitis Bmedicine.disease_causemedicine.diseaseGastroenterologydigestive system diseasesHBeAgInternal medicineHepatocellular carcinomaMedicineDecompensationbusinessHepatology
researchProduct

Perceived stress symptoms in midlife predict disability in old age: a 28-year prospective cohort study.

2013

Background Stress has damaging effects on individual's health. However, information about the long-term consequences of mental stress is scarce. Methods This 28-year prospective cohort study examined on the associations between midlife stress and old age disability among 2,994 Finnish municipal professionals aged 44-58 years at baseline. Self-reported stress symptoms were assessed at baseline in 1981 and 4 years later in 1985 and perceived disability in 2009. For the baseline data, principal component analysis was used for differentiation into stress symptom profiles. The regression coefficient estimates for self-care disability (activities of daily living) and instrumental activities of da…

GerontologyAdultMalemedicine.medical_specialtyAgingActivities of daily livingLogistic regressionCohort StudiesRisk FactorsEpidemiologyActivities of Daily LivingmedicineHumansDecompensationDisabled PersonsProspective StudiesMobility LimitationProspective cohort studyFinlandAgedAged 80 and overbusiness.industryPublic healthta3141Cognitionta3142Odds ratioMiddle AgedFemaleGeriatrics and GerontologybusinessStress PsychologicalThe journals of gerontology. Series A, Biological sciences and medical sciences
researchProduct

Care Dependency in Patients with Heart Failure: A Cross-Sectional Study in Spain.

2020

Background: Heart failure (HF) is a progressive and debilitating condition that represents an ever-growing problem for health systems worldwide. HF patients feel that they are a burden on their families, they feel socially isolated and have a low perception of their health. Accordingly, the objectives of this study were to: (1) to explore the profile of care dependency in a representative sample of Spanish HF patients through the Care Dependency Scale (CDS), and (2) to identify correlates of care dependency in this population. Material and Methods: We performed a cross-sectional study of 187 patients admitted for HF decompensation to the Hospital Clínico of Zaragoza (Spain). Results: Only 1…

GerontologyMaleCross-sectional studyHealth Toxicology and MutagenesisPopulationDependency Psychologicalheart failurelcsh:Medicine030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicinePatient AdmissionPersonal hygienenursingcare dependency heart failure nursingSickness Impact ProfileSurveys and QuestionnairesActivities of Daily LivingmedicineHumansDecompensation030212 general & internal medicinecareeducationAgedAged 80 and overeducation.field_of_studybusiness.industryBrief ReportCare dependencylcsh:RPublic Health Environmental and Occupational HealthPatient Acuitymedicine.diseaseHospitalsCross-Sectional StudiesSpainHeart failureScale (social sciences)Quality of LifeFemalebusinessdependencyDependency (project management)
researchProduct

Employment of vasopressin receptor antagonists in management of hyponatraemia and volume overload in some clinical conditions

2015

Summary What is known and objective Hyponatraemia, the most common electrolyte imbalance occurring in hospitalized subjects, is usually classified as hypovolaemic, euvolaemic or hypervolaemic. Hyponatraemia is a predictor of death among subjects with chronic heart failure and cirrhosis. The inappropriate secretion of the antidiuretic hormone (AVP) seems to be of pivotal importance in the decline of serum sodium concentration in these clinical conditions. The objective of this review was to summarize recent progress in management of hyponatraemia in SIADH, cirrhosis and heart failure. Methods Literature searches were conducted on the topics of hyponatraemia and vasopressin receptor antagonis…

Heart FailureLiver CirrhosisPharmacologyAquapheresismedicine.medical_specialtyCirrhosisbusiness.industrymedicine.medical_treatmentSodiumVolume overloadmedicine.diseasePlaceboHypertonic salineInappropriate ADH SyndromeAnesthesiaHeart failuremedicineHumansPharmacology (medical)DecompensationbusinessIntensive care medicineAntidiuretic Hormone Receptor AntagonistsHyponatremiaAntidiureticJournal of Clinical Pharmacy and Therapeutics
researchProduct

Cardiorenal Syndrome in Acute Heart Failure: Revisiting Paradigms

2015

A B S T R A C T Cardiorenal syndrome has been defined as the simultaneous dysfunction of both the heart and the kidney. Worsening renal function that occurs in patients with acute heart failure has been classified as cardiorenal syndrome type 1. In this setting, worsening renal function is a common finding and is due to complex, multifactorial, and not fully understood processes involving hemodynamic (renal arterial hypoperfusion and renal venous congestion) and nonhemodynamic factors. Traditionally, worsening renal function has been associated with worse outcomes, but recent findings have revealed mixed and heterogeneous results, perhaps suggesting that the same phenotype represents a dive…

Heart Failuremedicine.medical_specialtyKidneyCardio-Renal Syndromebusiness.industryHemodynamicsHemodynamicsRenal functionGeneral MedicineCardiorenal syndromeurologic and male genital diseasesmedicine.diseasePathophysiologymedicine.anatomical_structureHeart failureAcute DiseasemedicineHumansDecompensationIntensive care medicinebusinessPerfusionRevista Española de Cardiología (English Edition)
researchProduct